Jingjin Che
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jingjin Che has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Kangyin Chen
Tianjin Key Laboratory of Ionic‐Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin China
3 shared publications- Kang-Yin Chen
Department of Cardiology, Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Tianjin Institute of Cardiology, 300211 Tianjin, China
2 shared publications Shuang Dou
Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China
2 shared publications- Tong Liu
Second Hospital of Tianjin Medical University
2 shared publications Xiaoyan Liu
Tianjin Key Laboratory of Ionic‐Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology The Second Hospital of Tianjin Medical University Tianjin China
2 shared publicationsXue Zhou
Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China
2 shared publications
Latest Publications
- 8 July 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (3) , 1812-1816
An Anomalous LAD Originating Separately From Right Coronary Sinus: A Case Report
Anomalous origination of left anterior descending branch (LAD) from the right sinus (LAD‐ACAOS) is extremely rare in anomalous aortic origin of a coronary artery from the opposite sinus of Valsalva (ACAOS), which is prone to be missed during invasive coronary angiography (CAG). We present a case with acute non‐ST elevation myocardial infarction (NSTEMI), in whom LAD‐ACAOS was demonstrated by CAG and computed tomography angiography (CTA). A 71‐year‐old man presented with ischemic chest pain and mildly elevated troponin I. He underwent CAG, and was found to have a separate ostium of LAD. CTA showed that the anomalous LAD originated from right sinus with a higher ostium than right coronary artery, and surrounded the lateral and anterior wall of pulmonary conus, ultimately went into anterior interventricular groove with myocardial bridging (MB) in the mid part. This is very rare case LAD‐ACAOS. The LAD‐ACAOS is of pre‐pulmonary subtype with a high ostium in right sinus of Valsava, and MB in the mid part. The case shows us a special anatomy of LAD‐ACAOS, and also suggests this subtype of non‐interarteries anomaly is not always be benign.
- 8 July 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (3) , 1812-1816
An Anomalous LAD Originating Separately From Right Coronary Sinus: A Case Report
Anomalous origination of left anterior descending branch (LAD) from the right sinus (LAD‐ACAOS) is extremely rare in anomalous aortic origin of a coronary artery from the opposite sinus of Valsalva (ACAOS), which is prone to be missed during invasive coronary angiography (CAG). We present a case with acute non‐ST elevation myocardial infarction (NSTEMI), in whom LAD‐ACAOS was demonstrated by CAG and computed tomography angiography (CTA). A 71‐year‐old man presented with ischemic chest pain and mildly elevated troponin I. He underwent CAG, and was found to have a separate ostium of LAD. CTA showed that the anomalous LAD originated from right sinus with a higher ostium than right coronary artery, and surrounded the lateral and anterior wall of pulmonary conus, ultimately went into anterior interventricular groove with myocardial bridging (MB) in the mid part. This is very rare case LAD‐ACAOS. The LAD‐ACAOS is of pre‐pulmonary subtype with a high ostium in right sinus of Valsava, and MB in the mid part. The case shows us a special anatomy of LAD‐ACAOS, and also suggests this subtype of non‐interarteries anomaly is not always be benign.
- Open Access
- 28 June 2023
- Published by Wiley in Clinical Cardiology
- Vol. 46 (8) , 930-936
Effects of sacubitril‐valsartan in the treatment of chronic heart failure patients with end‐stage renal disease undergoing dialysis
Background: The data on the effects of the angiotensin receptor–neprilysin inhibitor (ARNI) sacubitril‐valsartan (LCZ696) in chronic heart failure (CHF) patients with end‐stage renal disease (ESRD) requiring dialysis are lacking. This study assessed the efficacy and safety of LCZ696 in CHF patients with ESRD on dialysis.Hypothesis: LCZ696 treatment can reduce rehospitalization rate for HF, delay the occurrence of rehospitalization for HF, and prolong the survival time.Methods: We retrospectively analyzed the clinical data of CHF patients with ESRD on dialysis who were admitted to the Second Hospital of Tianjin Medical University from August 2019 to October 2021.Results: Sixty‐five patients had primary outcome during the follow‐up. The incidence of rehospitalization for HF in the control group was significantly higher than that in the LCZ696 group (73.47% vs. 43.28%, p = .001). There was no significant difference in mortality between the two groups (8.96% vs. 10.20%, p = 1.000). Our study included a time‐to‐event analysis through 1 year for the primary outcome—Kaplan–Meier curve showed that the LCZ696 group had significantly longer free‐event survival time than the control group over 1‐year follow‐up (median survival time 139.0 days vs. 116.0 days, p = .037).Conclusions: Our study found that LCZ696 treatment was associated with a reduction in HF rehospitalization without significant effects on serum creatinine and serum potassium levels. LCZ696 is effective and safe in CHF patients with ESRD on dialysis.
- 28 June 2023
- Published by Wiley in Clinical Cardiology
- Vol. 46 (8) , 930-936
Open AccessEffects of sacubitril‐valsartan in the treatment of chronic heart failure patients with end‐stage renal disease undergoing dialysis
Background: The data on the effects of the angiotensin receptor–neprilysin inhibitor (ARNI) sacubitril‐valsartan (LCZ696) in chronic heart failure (CHF) patients with end‐stage renal disease (ESRD) requiring dialysis are lacking. This study assessed the efficacy and safety of LCZ696 in CHF patients with ESRD on dialysis.Hypothesis: LCZ696 treatment can reduce rehospitalization rate for HF, delay the occurrence of rehospitalization for HF, and prolong the survival time.Methods: We retrospectively analyzed the clinical data of CHF patients with ESRD on dialysis who were admitted to the Second Hospital of Tianjin Medical University from August 2019 to October 2021.Results: Sixty‐five patients had primary outcome during the follow‐up. The incidence of rehospitalization for HF in the control group was significantly higher than that in the LCZ696 group (73.47% vs. 43.28%, p = .001). There was no significant difference in mortality between the two groups (8.96% vs. 10.20%, p = 1.000). Our study included a time‐to‐event analysis through 1 year for the primary outcome—Kaplan–Meier curve showed that the LCZ696 group had significantly longer free‐event survival time than the control group over 1‐year follow‐up (median survival time 139.0 days vs. 116.0 days, p = .037).Conclusions: Our study found that LCZ696 treatment was associated with a reduction in HF rehospitalization without significant effects on serum creatinine and serum potassium levels. LCZ696 is effective and safe in CHF patients with ESRD on dialysis.
- 24 April 2021
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 36 (3) , 455-465
CD36+/CD61+ Microparticles Correlate with the Risk of Percutaneous Cardiac Interventions in Coronary Artery Disease Patients and the Effects of Ticagrelor
Purpose The CD36 scavenger receptor is a mediator of both atherogenesis and thrombosis. We aimed to investigate the prognostic value of CD36+ microparticles (MPs) released from platelets for cardiovascular event presentation in coronary artery disease (CAD) patients and the effects of different antiplatelet drugs on MPs. Methods A total of 101 aspirin-treated CAD patients, who were planned to undergo coronary angiography (CAG), were randomized to either a standard clopidogrel regimen or ticagrelor treatment. Total Annexin V-(AV)+ MPs, CD61+/AV+ MPs, and CD36+/CD61+/AV+ MPs were quantified by flow cytometry at baseline, before and immediately after the operation. The ADP-induced platelet inhibition rate was measured by thromboelastogram (TEG) examination 1 h before the operation. Results The baseline levels of CD36+/CD61+/AV+ MPs were significantly increased in percutaneous coronary intervention (PCI) patients (n = 52) compared to no-PCI patients (n = 49) (p < 0.05). A ROC-curve clustered model for CD36+/CD61+/AV+ MPs at baseline predicted an increased risk of PCI [p = 0.009, AUC = 0.761 (95%CI: 0.601 to 0.922)]. Moreover, TEG examination showed that the preoperative proportion of CD36+/CD61+/AV+ MPs was significantly negatively correlated with R time and K time (r = − 0.236, p = 00.026; r = − 0.288, p = 0.006), and positively correlated with MAADP (r = 0.226, p = 0.045). Subgroup analysis of PCI group showed that the platelet inhibition rate of ticagrelor was significantly higher (66.05% ± 28.76% vs.31.01% ± 27.33%, p < 0.001), and the number of AV+ MPs, CD61+/AV+ MPs, and CD36+/CD61+/AV+ MPs before the operation was significantly lower than clopidogrel (p < 0.05, all). Conclusion The high levels of CD36+ MPs derived from activated platelets are related to an increased risk of PCI in CAD patients. Ticagrelor significantly reduced the number of CD61+/AV+ MPs and CD36+/CD61+/AV+ MPs. This trial registration number is ChiCTR1800014908 and the date of registration is 2018.05.01.
- 24 April 2021
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 36 (3) , 455-465
CD36+/CD61+ Microparticles Correlate with the Risk of Percutaneous Cardiac Interventions in Coronary Artery Disease Patients and the Effects of Ticagrelor
Purpose The CD36 scavenger receptor is a mediator of both atherogenesis and thrombosis. We aimed to investigate the prognostic value of CD36+ microparticles (MPs) released from platelets for cardiovascular event presentation in coronary artery disease (CAD) patients and the effects of different antiplatelet drugs on MPs. Methods A total of 101 aspirin-treated CAD patients, who were planned to undergo coronary angiography (CAG), were randomized to either a standard clopidogrel regimen or ticagrelor treatment. Total Annexin V-(AV)+ MPs, CD61+/AV+ MPs, and CD36+/CD61+/AV+ MPs were quantified by flow cytometry at baseline, before and immediately after the operation. The ADP-induced platelet inhibition rate was measured by thromboelastogram (TEG) examination 1 h before the operation. Results The baseline levels of CD36+/CD61+/AV+ MPs were significantly increased in percutaneous coronary intervention (PCI) patients (n = 52) compared to no-PCI patients (n = 49) (p < 0.05). A ROC-curve clustered model for CD36+/CD61+/AV+ MPs at baseline predicted an increased risk of PCI [p = 0.009, AUC = 0.761 (95%CI: 0.601 to 0.922)]. Moreover, TEG examination showed that the preoperative proportion of CD36+/CD61+/AV+ MPs was significantly negatively correlated with R time and K time (r = − 0.236, p = 00.026; r = − 0.288, p = 0.006), and positively correlated with MAADP (r = 0.226, p = 0.045). Subgroup analysis of PCI group showed that the platelet inhibition rate of ticagrelor was significantly higher (66.05% ± 28.76% vs.31.01% ± 27.33%, p < 0.001), and the number of AV+ MPs, CD61+/AV+ MPs, and CD36+/CD61+/AV+ MPs before the operation was significantly lower than clopidogrel (p < 0.05, all). Conclusion The high levels of CD36+ MPs derived from activated platelets are related to an increased risk of PCI in CAD patients. Ticagrelor significantly reduced the number of CD61+/AV+ MPs and CD36+/CD61+/AV+ MPs. This trial registration number is ChiCTR1800014908 and the date of registration is 2018.05.01.
- Open Access
Effect of Calcium Dobesilate in Preventing Contrast-Induced Nephropathy in Patients with Diabetes and Chronic Kidney Disease
This study assessed the protective effect of calcium dobesilate against contrast-induced nephropathy (CIN) after coronary angiography (CAG) or percutaneous coronary intervention (PCI) in patients with diabetes and chronic kidney disease (CKD).A total ...
Open AccessEffect of Calcium Dobesilate in Preventing Contrast-Induced Nephropathy in Patients with Diabetes and Chronic Kidney Disease
This study assessed the protective effect of calcium dobesilate against contrast-induced nephropathy (CIN) after coronary angiography (CAG) or percutaneous coronary intervention (PCI) in patients with diabetes and chronic kidney disease (CKD).A total ...
- Open Access
- 20 June 2020
- Published by Wiley in Cardiology Research and Practice
- Vol. 2020, 1-8
Biomarkers for Predicting Left Atrial or Left Atrial Appendage Thrombus in Anticoagulated Patients with Nonvalvular Atrial Fibrillation
Purpose. Although atrial fibrillation (AF) is often associated with thromboembolic complications, there is no definite biomarker for detecting the presence of thrombi in the left atrial (LA) or left atrial appendage (LAA) in patients with nonvalvular atrial fibrillation (NVAF). Methods. NVAF patients who underwent transesophageal echocardiography (TEE) to evaluate LA/LAA thrombus and spontaneous echo contrast (SEC) before AF ablation were included. Multivariate logistic regression and receiver operating characteristic curve (ROC) analyses were performed to explore the independent risk factors of LA/LAA thrombus and indicate the best cutoff point. Results. Of the 260 consecutive subjects (mean age: 63.67 ± 9.39 years; 42% women), 45 (17.3%) patients were with LA/LAA thrombus, 131 (50.4%) were with SEC, and 84 (32.3%) were with neither thrombus nor SEC. The results of multivariate logistic regression analysis showed that N-terminal pro-B-type natriuretic peptide (NT-proBNP) (OR, 2.179; 95% CI: 1.191–3.987; ) and red cell distribution width (RDW) (OR, 2.398; 95% CI: 1.075–5.349; ) were independently correlated with the presence of LA/LAA thrombus but not D-dimer (OR, 0.999; 95% CI: 0.998–1.000; ). When all patients were divided into four groups based on the combination between RDW (cutoff value: 12.95%) and NT-proBNP levels (cutoff value: 368.9 ng/L), the rate of LA/LAA thrombus was the highest in the high RDW and NT-proBNP group. Conclusion. In anticoagulation patients with NVAF, elevated NT-proBNP and RDW are related to LA/LAA thrombus. Therefore, these might be considered as useful prognostic markers in the management and treatment of NVAF patients.- 20 June 2020
- Published by Wiley in Cardiology Research and Practice
- Vol. 2020, 1-8
Open AccessBiomarkers for Predicting Left Atrial or Left Atrial Appendage Thrombus in Anticoagulated Patients with Nonvalvular Atrial Fibrillation
Purpose. Although atrial fibrillation (AF) is often associated with thromboembolic complications, there is no definite biomarker for detecting the presence of thrombi in the left atrial (LA) or left atrial appendage (LAA) in patients with nonvalvular atrial fibrillation (NVAF). Methods. NVAF patients who underwent transesophageal echocardiography (TEE) to evaluate LA/LAA thrombus and spontaneous echo contrast (SEC) before AF ablation were included. Multivariate logistic regression and receiver operating characteristic curve (ROC) analyses were performed to explore the independent risk factors of LA/LAA thrombus and indicate the best cutoff point. Results. Of the 260 consecutive subjects (mean age: 63.67 ± 9.39 years; 42% women), 45 (17.3%) patients were with LA/LAA thrombus, 131 (50.4%) were with SEC, and 84 (32.3%) were with neither thrombus nor SEC. The results of multivariate logistic regression analysis showed that N-terminal pro-B-type natriuretic peptide (NT-proBNP) (OR, 2.179; 95% CI: 1.191–3.987; ) and red cell distribution width (RDW) (OR, 2.398; 95% CI: 1.075–5.349; ) were independently correlated with the presence of LA/LAA thrombus but not D-dimer (OR, 0.999; 95% CI: 0.998–1.000; ). When all patients were divided into four groups based on the combination between RDW (cutoff value: 12.95%) and NT-proBNP levels (cutoff value: 368.9 ng/L), the rate of LA/LAA thrombus was the highest in the high RDW and NT-proBNP group. Conclusion. In anticoagulation patients with NVAF, elevated NT-proBNP and RDW are related to LA/LAA thrombus. Therefore, these might be considered as useful prognostic markers in the management and treatment of NVAF patients.